BLS Pharma alleges that Inovio Pharmaceuticals Inc. and Genetronics Inc.'s breach of a supply agreement cost the company at least $72.9 million in profits.

BLS filed a complaint against the biotechnology companies last month for going back on an agreement to supply it with 25,000 units of Zetajet, a needle-free syringe developed by shareholders of BLS, who sold its rights to Inovio and Genetronics.

The rights were sold with the condition that Genetronics would execute a license and supply agreement to supply Zetajet units to BLS Pharma upon request.

BLS claims that it could not sell its testosterone replacement therapy because Inovio and Genetronics refused to supply the syringes, according to a Jan. 7 press release.

The company's therapy treats male hypogonadism, a condition in which the body has a reduced ability to produce testosterone.